Literature DB >> 15025524

Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.

Hong M Moulton1, Michelle H Nelson, Susie A Hatlevig, Muralimohan T Reddy, Patrick L Iversen.   

Abstract

Although the sequence specificity, biostability, and low toxicity of PMO (phosphorodiamidate morpholino oligomers) make them good antisense agents to study gene function, their limited ability to cross cell membranes limits their use in cell culture. In this paper we show that conjugation to arginine-rich peptides significantly enhanced the cellular uptake of PMO. The factors that affect the conjugate's cellular uptake and its antisense activity toward a targeted mRNA were investigated. Factors studied include the number of arginines in the peptide, the choice of cross-linker, the peptide conjugation position, the length of the PMO, and the cell culture conditions. Delivery of PMO to the cell nucleus and cytosol required conjugation rather than complexation of peptides to PMO. R(9)F(2)C was best suited to deliver a PMO to its target RNA resulting in the strongest antisense effect. By simply adding the R(9)F(2)C-PMO conjugate into the cell culture medium at low microM concentration, missplicing of pre-mRNA was corrected. This particular peptide-conjugated PMO was more effective than the PMO conjugated to the transmembrane transport peptides of HIV-1 Tat protein, Drosophila antennapedia protein, or to peptides with fewer arginines. Length of PMO did not affect a peptide's delivery efficacy, but all other factors were important. R(9)F(2)C peptide provided a simple and efficient delivery of PMO to a RNA target. Conjugation of peptide to PMO enhances the opportunities to evaluate gene functions in cell cultures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025524     DOI: 10.1021/bc034221g

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  76 in total

1.  Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.

Authors:  Catherine L Watkins; Edward J Sayers; Chris Allender; David Barrow; Christopher Fegan; Paul Brennan; Arwyn T Jones
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.

Authors:  Tia S Deas; Iwona Binduga-Gajewska; Mark Tilgner; Ping Ren; David A Stein; Hong M Moulton; Patrick L Iversen; Elizabeth B Kauffman; Laura D Kramer; Pei-Yong Shi
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus.

Authors:  Jeffrey K Stone; Rene Rijnbrand; David A Stein; Yinghong Ma; Yan Yang; Patrick L Iversen; Raul Andino
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

4.  Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Rheba S Bonaparte; Deendayal Patel; David A Stein; Patrick L Iversen
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

5.  Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.

Authors:  Benjamin W Neuman; Lydia H Bederka; David A Stein; Joey P C Ting; Hong M Moulton; Michael J Buchmeier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 6.  Update on the treatment of Duchenne muscular dystrophy.

Authors:  Louise R Rodino-Klapac; Jerry R Mendell; Zarife Sahenk
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

7.  Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome.

Authors:  Paola Scaffidi; Tom Misteli
Journal:  Nat Med       Date:  2005-03-06       Impact factor: 53.440

8.  Endocytosis and intracellular trafficking properties of transferrin-conjugated block copolypeptide vesicles.

Authors:  Uh-Joo Choe; April R Rodriguez; Brian S Lee; Scott M Knowles; Anna M Wu; Timothy J Deming; Daniel T Kamei
Journal:  Biomacromolecules       Date:  2013-04-26       Impact factor: 6.988

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

10.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.